LON:IQAI

IQ-AI (IQAI) Share Forecast, Price & News

GBX 3.90

0.00 (0.00%)

(As of 05/20/2022 12:00 AM ET)

Add

Compare

Today's Range: 3.84
▼
3.95
50-Day Range: 3.85
▼
5
52-Week Range: 3.78
▼
11.10

Volume: 207,818 shs
Average Volume: 455,575 shs
Market Capitalization: £7.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive IQAI News and Ratings via Email

Sign-up to receive the latest news and ratings for IQ-AI and its competitors with MarketBeat's FREE daily newsletter.

About IQ-AI

IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States. Its products include IB Clinic, a toolkit of post-processing software plug-ins for integrating into existing medical image visualization applications; IB Rad Tech, a workflow engine that processes customized workflows; IB Neuro, which analyzes MR data sets and generates parametric perfusion maps quantifying changes in contrast over time; and IB Delta Suite that performs a various fundamental radiology operations, including image co-registration, subtraction, class map generation, and export. The company also offers IB DCE, which analyzes conventional T1 weighted images and generates an array of relevant perfusion and permeability parameters; IB Diffusion that analyzes MR diffusion-weighted images and generates apparent diffusion coefficient, extrapolated b-value, IVIM, and other parameter maps; and StoneChecker, a medical software tool to aid clinical decision making by providing information about a patient's kidney stone. In addition, it provides consulting services. The company was formerly known as Flying Brands Limited and changed its name to IQ-AI Limited in October 2018. IQ-AI Limited is based in Saint Helier, Jersey.

May 13, 2022 | americanbankingnews.com

IQ-AI (LON:IQAI) Trading Down 0%

May 4, 2022 | finanznachrichten.de

IQ AI Ltd.: IB Neuro's Quantitative Mapping Method Assesses Metastatic Tumors

May 3, 2022 | finance.yahoo.com

IB Neuro's Quantitative Mapping Method Assesses Metastatic Tumors

April 29, 2022 | proactiveinvestors.com.au

IQ-AI doubles revenues as hospitals resume normal business

April 21, 2022 | msn.com

The "world's shortest" IQ test only has three questions and a 17 per cent pass rate

April 21, 2022 | msn.com

The 'World's shortest' IQ test with only three questions might leave you scratching your head

March 11, 2022 | proactiveinvestors.com

IQ-AI starts enrolment for brain cancer treatment trial

March 10, 2022 | finanznachrichten.de

IQ AI Ltd.: IQAI's Sponsored Phase I Clinical Trial is Open

March 10, 2022 | apnews.com

IQAI’s Sponsored Phase I Clinical Trial is Open

March 10, 2022 | finance.yahoo.com

IQAI's Sponsored Phase I Clinical Trial is Open

March 7, 2022 | finanznachrichten.de

IQ AI Ltd.: Imaging Biometrics Touts Position Paper for Monitoring High-Grade Glioma Treatment Response

March 7, 2022 | finance.yahoo.com

Imaging Biometrics Touts Position Paper for Monitoring High-Grade Glioma Treatment Response

January 27, 2022 | finanznachrichten.de

IQ AI Ltd.: Imaging Biometrics LLC - Letter to Shareholders

See More Headlines

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Health Information Services
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:IQAI
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.imagingbiometrics.com
Phone: N/A
Fax: N/A
Employees: 7
Year Founded: N/A

Sales & Book Value

Annual Sales: £521.07 thousand
Price / Sales: 13.67
Cash Flow: GBX 0.38 per share
Price / Cash Flow: 10.38
Book Value: GBX 0.70 per share
Price / Book: 5.57

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 8.71
Current Ratio: 2.05
Quick Ratio: 2.05

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 182,621,000
Free Float: N/A
Market Cap: £7.12 million
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.88 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for IQ-AI.

4.4 Community Rank

Outperform Votes
IQ-AI has received 6 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IQ-AI has received 3 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IQ-AI has received 66.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IQ-AI and other stocks. Vote “Outperform” if you believe IQAI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IQAI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
IQ-AI does not currently pay a dividend.
Dividend Growth
IQ-AI does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IQ-AI insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of IQ-AI is -13.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IQ-AI is -13.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IQ-AI has a P/B Ratio of 5.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

IQ-AI (LON:IQAI) Frequently Asked Questions

Who are IQ-AI's key executives?: IQ-AI's management team includes the following people:
Mr. Trevor Edward Brown M.B.A., CEO & Director (Age 76, Pay $100k)
Mr. David W. J. Smith, Chief Operating Officer
Donald Reid, Sec.
Who are some of IQ-AI's key competitors?: Some companies that are related to IQ-AI include DIAGNOS (ADK), CardioComm Solutions (EKG), Sensyne Health (SENS), ZoomMed (ZMD), 1st Group (1ST), Alcidion Group (ALC), Artrya (AYA), Binovi Technologies (BNVIF), Cann American (CNNA), Carebook Technologies (CRBKF), Careteq (CTQ), CloudMD Software & Services (DOCRF), Cogstate (CGS), Corum Group (COO) and Dialogue Health Technologies (CARE.TO).
View all of IQAI's competitors.
What other stocks do shareholders of IQ-AI own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IQ-AI investors own include Macerich (MAC), Merck & Co., Inc. (MRK), Pfizer (PFE), Scotts Miracle-Gro (SMG), Xilinx (XLNX), Arista Networks (ANET), Amgen (AMGN), Advanced Micro Devices (AMD), Akers Biosciences (AKER) and Aimmune Therapeutics (AIMT).
What is IQ-AI's stock symbol?: IQ-AI trades on the London Stock Exchange (LON) under the ticker symbol "IQAI."
How do I buy shares of IQ-AI?: Shares of IQAI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is IQ-AI's stock price today?: One share of IQAI stock can currently be purchased for approximately GBX 3.90.
How much money does IQ-AI make?: IQ-AI has a market capitalization of £7.12 million and generates £521.07 thousand in revenue each year.
How many employees does IQ-AI have?: IQ-AI employs 7 workers across the globe.
What is IQ-AI's official website?: The official website for IQ-AI is www.imagingbiometrics.com.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.